FBDSOTCinactive

Fuss Brands Corp.

Financial Services·Neurology·Commercial·New York, NY, United States
NeurologyCardiovascularInfectious DiseaseRespiratoryPainNephrologyPsychiatry

Fuss Brands Corp. (FBDS): 10 pipeline candidates · ~0 mo cash runway. Updated within the last hour.

7.5/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.0

0.1 months

Financial Health10.0

D/E -1.28 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

10 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Fuss Brands Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$2.2M

Cash

$633

Quarterly Burn

$26K

Runway

0.1 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2026
Today~7 mo out
Catalyst within runway

Pipeline (10 candidates)

·CEO: Mr. Cheskel Meisels

Frequently asked questions

How many drug candidates are in Fuss Brands Corp.'s pipeline?

Fuss Brands Corp. (FBDS) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Fuss Brands Corp.'s lead drug candidate?

Fuss Brands Corp.'s most advanced tracked candidate is badger oil (Approved) for Burn and scald.

What is Fuss Brands Corp.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Fuss Brands Corp. has approximately 0.1 months of cash runway.

What is Fuss Brands Corp.'s market capitalization?

Fuss Brands Corp.'s market capitalization is approximately $2.2M.

Who is the CEO of Fuss Brands Corp.?

Mr. Cheskel Meisels is the chief executive officer of Fuss Brands Corp. (FBDS).

Get the full picture on Fuss Brands Corp.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.